Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 25.81M P/E - EPS this Y -162.50% Ern Qtrly Grth -
Income -13.34M Forward P/E -0.95 EPS next Y 214.30% 50D Avg Chg 1.00%
Sales 36.08M PEG - EPS past 5Y 24.21% 200D Avg Chg -25.00%
Dividend N/A Price/Book 0.88 EPS next 5Y - 52W High Chg -77.00%
Recommedations 2.00 Quick Ratio 1.71 Shares Outstanding 35.25M 52W Low Chg 56.00%
Insider Own 36.42% ROA -14.08% Shares Float 17.76M Beta 1.67
Inst Own 21.57% ROE -48.92% Shares Shorted/Prior 396.87K/408.90K Price 0.75
Gross Margin 100.00% Profit Margin -36.96% Avg. Volume 193,314 Target Price -
Oper. Margin -34.74% Earnings Date May 9 Volume 2,867,938 Change 2.70%
About Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Equillium, Inc. News
05/02/24 We're Keeping An Eye On Equillium's (NASDAQ:EQ) Cash Burn Rate
07:00 AM Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/01/24 5 Stocks That More Than Doubled in Q1 With More Gains Ahead
04/01/24 Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
03/25/24 Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
03/25/24 Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
03/22/24 Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference
03/22/24 Individual investors account for 41% of Equillium, Inc.'s (NASDAQ:EQ) ownership, while insiders account for 20%
03/04/24 The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark
03/01/24 5 Stocks That More Than Doubled in February
02/23/24 5 Top-Ranked Stocks That Have More Than Doubled Year to Date
02/09/24 Even after rising 85% this past week, Equillium (NASDAQ:EQ) shareholders are still down 85% over the past three years
01/29/24 15 Cash-Rich Penny Stocks Hedge Funds Are Buying
12/21/23 Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
11/20/23 EQ Bank Card launches in Québec as Carte Banque EQ
11/13/23 Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology
11/08/23 Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
11/06/23 Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology
10/24/23 10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
10/19/23 Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology
EQ Chatroom

User Image VinWeezel Posted - 04/30/24

$EQ

User Image RavesRamirez Posted - 04/19/24

$EQ @aaronr @BLitt my guess is they just want the option to RS ,just in case..., and prefer to get it now instead of asking for it when it gets rough. This way the impact on SP might be just short term, they can buy back some more (cheaper) shares or enable insiders to buy at lower prices because of the little shortterm setback in SP. Once positive news hits, the SP regains the losses quickly and the possibility of an RS is forgotten. Just my 2cents...

User Image BLitt Posted - 04/18/24

$EQ Clown👇

User Image Wisenheimer Posted - 04/12/24

$EQ they weren’t going to file for a reverse but just did

User Image RavesRamirez Posted - 04/10/24

$EQ a bit curious that the SP fell after the rather good news and positive PT signals by HC and so on. Will be interesting to see what Ono will do, if I remember correct the phase 2 was one of the milestones with payment https://thefly.com/permalinks/entry.php/id3889875/EQ-Equillium-announces-topline-data-from-Type-B-portion-of-EQUALISE-study-1711973259

User Image BigLineSwings Posted - 04/04/24

$EQ this is going to do a thing one day soonish . Once this gets and stays above 4-5$ + bucks eyes will be on it . Long term

User Image Stock_Titan Posted - 1 month ago

$EQ Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/EQ/equillium-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-2maekyb8tgce.html

User Image SolidTrades Posted - 1 month ago

$QQQ Today morning down due to margin calls on $es & $eq?

User Image GSP Posted - 1 month ago

Gap play watch list for today (so far): $XLO $VSTE $SMR $GOEV $EQ

User Image hedge170 Posted - 1 month ago

$EQ https://www.businesswire.com/news/home/20240401373328/en/?s=09

User Image Stock_Titan Posted - 1 month ago

$EQ Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis https://www.stocktitan.net/news/EQ/equillium-announces-positive-topline-data-from-the-type-b-portion-of-7v8cq3l2jo9j.html

User Image VinWeezel Posted - 03/29/24

$EQ the year of eq continues

User Image Bionco Posted - 03/28/24

$EQ nice pop-up today

User Image LabPsycho Posted - 03/26/24

$EQ Just my opinion, but based on their news, finances and trend of other small biotechs - the 'cash runway' to mid 2025 usually means to me a dilution is coming 9-12 months before the runway runways out. Biotechs don't wait till the last day to raise cash. If EQ does get a payment from Ono option exercise, I would expect a follow-on offering. Coupled with the rapid 250% increase in EQ, I think this could retrace even more as investors seal in profits. Wild speculation.

User Image nevermind889 Posted - 03/26/24

$EQ Why is this down so much?

User Image _www_larval_com_ Posted - 03/26/24

$EQ has dropped -12% lower to -22% (~78Kv) in the last few minutes, 04/19 options, follow for more volatility.

User Image B9YCE Posted - 03/26/24

$EQ gimme more shares @2.40!

User Image VinWeezel Posted - 03/25/24

$EQ catalysts upcoming.

User Image DonCorleone77 Posted - 03/25/24

$EQ Equillium reports Q4 EPS (7c) vs. 8c last year Reports Q4 revenue $9.2M vs. $15.7M last year. "The past year we have been focused on clinical execution that has set up the potential milestones we have in front of us in 2024," said Bruce Steel, CEO. "The Phase 1b EQUALISE study of itolizumab in patients with lupus nephritis is now complete. We presented positive data from this study at the annual meetings of both ASN and ACR in the fourth quarter last year and we expect to deliver the topline data to our partner Ono in the coming weeks. We expect to announce the results of the interim review by the data monitoring committee of our Phase 3 EQUATOR study of itolizumab in patients with acute graft-versus-host disease in the third quarter, which would represent the final data deliverable to trigger Ono's option exercise period, which will expire three months following such deliverables.....

User Image Stock_Titan Posted - 03/25/24

$EQ Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights https://www.stocktitan.net/news/EQ/equillium-reports-on-fourth-quarter-and-full-year-2023-financial-8gsxeyfmcvar.html

User Image ButterCapital Posted - 03/25/24

$EQ might add some more

User Image ButterCapital Posted - 03/22/24

$EQ am i too late?

User Image Stocks4thought Posted - 03/22/24

$EQ Did partner step in yet?

User Image Stock_Titan Posted - 03/22/24

$EQ Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference https://www.stocktitan.net/news/EQ/equillium-to-present-at-the-h-c-wainwright-autoimmune-amp-kwrz079ikgxm.html

User Image B9YCE Posted - 03/21/24

$EQ we like it here. HODL.

User Image fda_tracker Posted - 03/18/24

$EQ Phase 2 trial w/est Mar completion date NCT05589610: https://www.clinicaltrials.gov/study/NCT05589610 Trial Tracker: https://www.fdatracker.com/trial-tracker/

User Image VinWeezel Posted - 03/17/24

$EQ higher highs incoming

User Image nevermind889 Posted - 03/07/24

$EQ Nice job!! Was tempted to get in at 8% in PM.... SMH I done goof not buying!!

User Image VinWeezel Posted - 03/07/24

$EQ

User Image RavesRamirez Posted - 03/06/24

@Bottleinthesmoke I'm curious, what makes you think $EQ will rise that quickly back to 3$? Eventually, sure, but why this week?

Analyst Ratings
HC Wainwright & Co. Buy Apr 2, 24
HC Wainwright & Co. Buy Dec 26, 23
HC Wainwright & Co. Buy Nov 13, 23
Cantor Fitzgerald Overweight Aug 14, 23
HC Wainwright & Co. Buy Aug 14, 23
HC Wainwright & Co. Buy May 15, 23
HC Wainwright & Co. Buy May 1, 23
Stifel Buy Mar 24, 23
SVB Leerink Outperform Feb 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Keyes Jason A Chief Financial Offi.. Chief Financial Officer Aug 29 Sell 2.83 7,000 19,810 77,720 08/30/22
Keyes Jason A Chief Financial Offi.. Chief Financial Officer Jun 06 Sell 2.52 5,000 12,600 84,720 06/06/22
Keyes Jason A Chief Financial Offi.. Chief Financial Officer Apr 04 Sell 3.18 8,000 25,440 89,720 04/05/22
Connelly Stephen Chief Scientific Off.. Chief Scientific Officer Oct 06 Option 3.78 8,092 30,588 995,467 10/07/21
Connelly Stephen Chief Scientific Off.. Chief Scientific Officer Oct 06 Sell 7.01 8,092 56,725 993,000 10/07/21